[Individualized therapy with alpha-interferon in metastatic renal cell carcinoma].
Thirty-two patients with metastatic renal cell carcinoma were treated as outpatients with individually dosed interferon alpha (IFN alpha). The individual maximum dose was based on the side effects. In 7 patients the course of the disease was influenced: 1 attained complete remission, 3 patients, partial remission and 3, stable disease. The outcome of therapy was not dose-dependent. Patients with lung metastases were more sensitive to IFN alpha than the others. Up to 20% of patients responded to the therapy.
Gross
A J
AJ
Klinik für Urologie, Klinikum Steglitz der FU Berlin.
Dieckmann
K P
KP
Krain
J
J
Huland
H
H
D000368:Aged; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000556:secondary* / Q000628:therapy; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D007680:Kidney Neoplasms / Q000473:pathology / Q000628:therapy*; D008175:Lung Neoplasms / Q000473:pathology / Q000556:secondary* / Q000628:therapy; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009392:Nephrectomy; D016896:Treatment Outcome
D016898:Interferon-alpha
Individualspezifische Therapie mit alpha-Interferon beim metastasierten Nierenzellkarzinom.